Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MET233 and MET097
MET233 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| (Part A) MET233 | EXPERIMENTAL | Participants will receive a single dose of MET233 at up to 5 dose levels |
| (Part A) Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo |
| (Part B) MET233 | EXPERIMENTAL | Participants will receive five weekly doses of MET233 at up to 4 dose levels |
| (Part B) Placebo | PLACEBO_COMPARATOR | Participants will receive five weekly doses of placebo |
| (Part C) MET233 | EXPERIMENTAL | Participants will receive twelve weekly doses of MET233 at up to 4 dose levels, followed by a 13th potential monthly dose |
| (Part C) Placebo | PLACEBO_COMPARATOR | Participants will receive twelve weekly doses of placebo, followed by a 13th potential monthly dose |
| (Part D) MET233 | EXPERIMENTAL | Participants will receive twelve weekly doses of MET233, followed by three monthly doses. |
| (Part D) Placebo | PLACEBO_COMPARATOR | Participants will receive twelve weekly doses of placebo, followed by three monthly doses. |
| Name | Type | Description |
|---|---|---|
| MET233 | BIOLOGICAL | For subcutaneous administration |
| Placebo | BIOLOGICAL | Sterile 0.9% (w/v) saline for subcutaneous administration |
Inclusion Criteria: * Adult (≥18 to ≤70 years) male and female participants with obesity or overweight (BMI 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy. Exclusion Criteria: * Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior ...
MET233 is an investigational monoclonal antibody being developed for obesity and obesity-related medical conditions, as well as for obesity and overweight. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MET233 is a monoclonal antibody, a type of biologic designed to target specific molecules in the body. However, its precise molecular target has not been disclosed in available information, so its exact mechanism of action is not publicly detailed.
MET233 is being developed by Metsera, Inc., a biopharmaceutical company publicly traded under the ticker symbol MTSR. The company is conducting clinical trials to evaluate the drug's safety and efficacy in individuals with obesity or overweight.
MET233 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The ongoing Phase 1 trials are designed to assess safety, tolerability, and preliminary efficacy.
MET233 is being studied in two Phase 1 clinical trials. One trial, NCT06924320, is recruiting and evaluates MET233 in combination with MET097 in individuals with obesity or overweight with or without diabetes. Another trial, NCT07022977, has been completed and studied MET233 alone in individuals with obesity or overweight.
MET233 is not the same as MET097. MET233 is a separate investigational monoclonal antibody, while MET097 is a different drug candidate. They are being studied together in a combination trial, but they are distinct therapeutic agents.